News

The R1507 antibody was created by Genmab under the company’s agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of $500,000. Lisa

This will be the first Phase II clinical trial for EHT 0202 and it will be a multi-center, double-blind trial, in which 135 patients will be randomized. The

Under the terms of the agreement, Merck Serono will make an upfront payment of E2 million to Flamel for investigating the therapeutic protein and Merck Serono will fund

Under the agreement, HGS has paid Aegera an upfront license fee of $15 million and has made an equity investment of C$5 million. Aegera will be entitled to

Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s AdVac vaccine technology and PER.C6 manufacturing technology. A Phase I clinical trial launched

Under the terms of the expanded agreement, Nektar will receive up to $44 million in upfront and milestone payments, funding of research and development, and manufacturing revenues during

The milestone payment arises from a drug discovery alliance with GSK to focus on the discovery of small-molecule TPO mimetics. Under the terms of the collaboration, Ligand is

Under the terms of the purchase agreement, the acquirer assumed all costs and liabilities of Solx as of December 1, 2007, in addition to a $5 million payment

The Phase II program is a multi-center, randomized, double-blind placebo- controlled study in patients with sleep maintenance insomnia (SMI). The primary endpoint is an assessment of objective slow